CoChat

European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background: Increased morbidity and mortality associated with conventional glucocorticoid replacement therapy for primary adrenal insufficiency (primary AI; estimated prevalence 93–140/million), secondary AI (estimated prevalence, 150–280/million, respectively) or congenital adrenal hyperplasia (estimated prevalence, approximately 65/million) may be due to the inability of typical glucocorticoid treatment regimens to reproduce the normal circadian profile of plasma cortisol. A once-daily modified-release formulation of hydrocortisone has been developed to provide a plasma cortisol profile that better mimics the daytime endogenous profile of cortisol. Here, we describe the protocol for the European Adrenal Insufficiency Registry (EU-AIR), an observational study to assess the long-term safety of modified-release hydrocortisone compared with conventional glucocorticoid replacement therapies in routine clinical practice (ClinicalTrials.gov identifier: NCT01661387). Methods: Patients enrolled in EU-AIR have primary or secondary AI and are receiving either modified-release or conventional glucocorticoid replacement therapy. The primary endpoints of EU-AIR are the incidence of intercurrent illness, adrenal crisis and serious adverse events (SAEs), as well as the duration of SAEs and dose changes related to SAEs. Data relating to morbidity, mortality, adverse drug reactions, dosing and concomitant therapies will be collected. Patient diaries will record illness-related dose changes between visits. All decisions concerning medical care are made by the registry physician and patient. Enrolment is targeted at achieving 3600 patient-years of treatment (1800 patient-years per group) for the primary analysis, which is focused on determining the non-inferiority of once-daily modified-release replacement therapy compared with conventional glucocorticoid therapy. Results: Recruitment began in August 2012 and, as of March 2014, 801 patients have been enrolled. Fifteen centres are participating in Germany, the UK and Sweden, with recruitment soon to be initiated in the Netherlands. Conclusions: EU-AIR will provide a unique opportunity not only to collect long-term safety data on a modified-release preparation of glucocorticoid but also to evaluate baseline data on conventional glucocorticoid replacement. Such data should help to improve the treatment of AI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1472-6823-14-40

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of the EU-AIR study design. EMA, European Medicines Agency.
Figure 1 Flow diagram of the EU-AIR study design. EMA, European Medicines Agency.CC BY · PubMed Central
Figure 2 Cumulative numbers of patients enrolled in EU-AIR since August 2012.
Figure 2 Cumulative numbers of patients enrolled in EU-AIR since August 2012.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. ViroPharma SPRL: Plenadren 5 mg Modified-Release Tablets: Summary of Product Characteristics. 2011

Cited by

See all 31

Metadata

Authors
Ekman, B., Fitts, D., Marelli, C., Murray, R. D., Quinkler, M., & Zelissen, P. M.
Affiliations
  • Linköping University (SE)
  • Leeds Teaching Hospitals NHS Trust (GB)
  • Charité – Universitätsmedizin Berlin (DE)
  • University Medical Center Utrecht (NL)
Corresponding author
Fitts, David
Venue
BMC Endocrine Disorders
Published
2014-05-09
Volume
14
Issue
1
Pages
40-40
ISSN
1472-6823 (ISSN-L)
OpenAlex
W2067842378
Cited by
31
References
32
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 5 · 2021: 6 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 1 · 2014: 1
FWCI
3.22
Type
journal article
Language
en
Open access
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
Funders
Viropharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
Addison's disease, secondary adrenal insufficiency, congenital adrenal hyperplasia, glucocorticoid replacement therapy, modified-release hydrocortisone, adrenal crisis, serious adverse events, non-inferiority, long-term treatment safety, patient registry
MeSH terms
Adolescent, Adrenal Insufficiency, Adrenal Hyperplasia, Congenital, Adult, Aged, Aged, 80 and over, Child, Circadian Rhythm, Europe, Female, Follow-Up Studies, Glucocorticoids, Humans, Hydrocortisone, Male, Middle Aged, Morbidity, Prognosis, Hormone Replacement Therapy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. https://app.cochat.ai/papers/10.1186/1472-6823-14-40
The paper
Ekman, B., Fitts, D., Marelli, C., Murray, R. D., Quinkler, M., & Zelissen, P. M. (2014). European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocrine Disorders. https://doi.org/10.1186/1472-6823-14-40

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.